Company / R&D per Share
Compass Therapeutics, Inc. R&D per Share History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.31
FY2024
5-year range
$0.24 / $0.48
FY2020-FY2024
Trend
+2.9%
vs FY2023
Sector context
#186 of 208
Health Care
What the data says
Compass Therapeutics, Inc.'s r&d per share of $0.31 is lower than 89% of companies in the Health Care sector (FY2024). Improved from $0.24 to $0.31 over the past 2 years.
Based on SEC 10-K filings.
0.31 in FY2024 with a 5-year CAGR of -38.0%.
Improved from $0.24 to $0.31 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -1.7%
- 5-Year CAGR
- -38.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 208This company $0.31 Sector average $28.77
▼
-98.9% below sector average
Key checks
Key Insights
- In FY2024, r&d per share increased 2.9% year-over-year.
- Ranks #186 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2019.
- Lowest r&d per share in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.31 | +2.9% |
| FY2023 | $0.30 | +25.7% |
| FY2022 | $0.24 | -26.6% |
| FY2021 | $0.32 | -33.2% |
| FY2020 | $0.48 | -85.6% |
| FY2019 | $3.36 | - |
| FY2018 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026